These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22300367)

  • 21. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
    Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
    Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
    Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
    Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
    Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.
    Merino G; Alvarez AI; Pulido MM; Molina AJ; Schinkel AH; Prieto JG
    Drug Metab Dispos; 2006 Apr; 34(4):690-5. PubMed ID: 16434544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
    Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
    Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
    Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
    J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
    Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
    Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate.
    Tomaru A; Morimoto N; Morishita M; Takayama K; Fujita T; Maeda K; Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2013; 28(1):71-4. PubMed ID: 22785334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship.
    Kumar V; Prasad B; Patilea G; Gupta A; Salphati L; Evers R; Hop CE; Unadkat JD
    Drug Metab Dispos; 2015 Feb; 43(2):284-8. PubMed ID: 25488931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.
    Murakami M; Ohnuma S; Fukuda M; Chufan EE; Kudoh K; Kanehara K; Sugisawa N; Ishida M; Naitoh T; Shibata H; Iwabuchi Y; Ambudkar SV; Unno M
    Drug Metab Dispos; 2017 Nov; 45(11):1166-1177. PubMed ID: 28904007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
    Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
    Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid detection of ABC transporter interaction: potential utility in pharmacology.
    Robey RW; Lin B; Qiu J; Chan LL; Bates SE
    J Pharmacol Toxicol Methods; 2011; 63(3):217-22. PubMed ID: 21112407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
    Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
    An G; Gallegos J; Morris ME
    Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
    Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
    Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.